Search

Your search keyword '"Beat M. Frey"' showing total 2 results
Start Over Author "Beat M. Frey" Publisher elsevier
2 results on '"Beat M. Frey"'

1. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Author

Marc Emmenegger, Elena De Cecco, David Lamparter, Raphaël P.B. Jacquat, Julien Riou, Dominik Menges, Tala Ballouz, Daniel Ebner, Matthias M. Schneider, Itzel Condado Morales, Berre Doğançay, Jingjing Guo, Anne Wiedmer, Julie Domange, Marigona Imeri, Rita Moos, Chryssa Zografou, Leyla Batkitar, Lidia Madrigal, Dezirae Schneider, Chiara Trevisan, Andres Gonzalez-Guerra, Alessandra Carrella, Irina L. Dubach, Catherine K. Xu, Georg Meisl, Vasilis Kosmoliaptsis, Tomas Malinauskas, Nicola Burgess-Brown, Ray Owens, Stephanie Hatch, Juthathip Mongkolsapaya, Gavin R. Screaton, Katharina Schubert, John D. Huck, Feimei Liu, Florence Pojer, Kelvin Lau, David Hacker, Elsbeth Probst-Müller, Carlo Cervia, Jakob Nilsson, Onur Boyman, Lanja Saleh, Katharina Spanaus, Arnold von Eckardstein, Dominik J. Schaer, Nenad Ban, Ching-Ju Tsai, Jacopo Marino, Gebhard F.X. Schertler, Nadine Ebert, Volker Thiel, Jochen Gottschalk, Beat M. Frey, Regina R. Reimann, Simone Hornemann, Aaron M. Ring, Tuomas P.J. Knowles, Milo A. Puhan, Christian L. Althaus, Ioannis Xenarios, David I. Stuart, and Adriano Aguzzi

Subjects
Immunology, Microbiology, Virology, Biological database, Science
Abstract

Summary: Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72′250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.

Published
2023
Full Text
View/download PDF

2. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large metropolitan region

Author

Marc Emmenegger, Elena De Cecco, David Lamparter, Raphaël P. B. Jacquat, Julien Riou, Dominik Menges, Tala Ballouz, Daniel Ebner, Mathias M. Schneider, Itzel Condado Morales, Berre Doğançay, Jingjing Guo, Anne Wiedmer, Julie Domange, Marigona Imeri, Rita Moos, Chryssa Zografou, Leyla Batkitar, Lidia Madrigal, Dezirae Schneider, Chiara Trevisan, Andres Gonzalez-Guerra, Alessandra Carrella, Irina L. Dubach, Catherine K. Xu, Georg Meisl, Vasilis Kosmoliaptsis, Tomas Malinauskas, Nicola Burgess-Brown, Ray Owens, Stephanie Hatch, Juthathip Mongkolsapaya, Gavin R. Screaton, Katharina Schubert, John D. Huck, Feimei Liu, Florence Pojer, Kelvin Lau, David Hacker, Elsbeth Probst-Müller, Carlo Cervia, Jakob Nilsson, Onur Boyman, Lanja Saleh, Katharina Spanaus, Arnold von Eckardstein, Dominik J. Schaer, Nenad Ban, Ching-Ju Tsai, Jacopo Marino, Gebhard F. X. Schertler, Nadine Ebert, Volker Thiel, Jochen Gottschalk, Beat M. Frey, Regina Reimann, Simone Hornemann, Aaron M. Ring, Tuomas P. J. Knowles, Milo A. Puhan, Christian L. Althaus, Ioannis Xenarios, David I. Stuart, and Adriano Aguzzi

Subjects
Veterinary medicine, education.field_of_study, biology, medicine.diagnostic_test, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Population, Serology, law.invention, Transmission (mechanics), law, Immunoassay, biology.protein, Medicine, Seroprevalence, Seroconversion, Antibody, business, education
Abstract

Effective public-health measures and vaccination campaigns against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against the ectodomain and the receptor-binding domain of the spike protein as well as the nucleocapsid protein of SARS-CoV-2. We used TRABI for continuous seromonitoring of hospital patients and healthy blood donors (n=72’222) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). Seroprevalence peaked in May 2020 and rose again in November 2020 in both cohorts. Validations of results included antibody diffusional sizing and Western Blotting. Using an extended Susceptible-Exposed-Infectious-Removed model, we found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020 in the population of the canton of Zurich. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19 and up to the timepoint of survey participation. Crucially, we found no evidence for a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2- infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results